atients older than 18 years old with stable chronic kidney disease and hypertension are included in this project. Patients with diabetes mellitus, patients on renal replacement therapy, patients on antihypertensive medication (which cannot be stopped), patients on immunosuppressive treatment are excluded.
Conditions
Interventions
Product Name: Lipitor 40 mg
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Sponsors
University medical center Utrecht
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients older than 18 years old with stable chronic kidney disease and hypertension are included in this project. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients with diabetes mellitus, patients on renal replacement therapy, patients on antihypertensive medication (which cannot be stopped), patients on immunosuppressive treatment are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: Secondary objectives to study the effect of atorvastatin on kidney function and PRA in hypertensive patients with CKD.;Primary end point(s): muscle sympathetic nerve activity (MSNA);Main Objective: The primary objective is to investigate the effect of a statin (atorvastatin) added to chronic ARB therapy on sympathetic activity in CKD patients. We expect that sympathetic activity will be further reduced. | — |
Countries
Netherlands
Outcome results
None listed